In patients with mild or moderate renal impairment, the use of novel oral anticoagulants appears to confer reduced risks for stroke or systemic embolism, as well as for major bleeding, compared with warfarin, according to research published in The American Journal of Cardiology.“We found that subjects with mild or moderate renal impairment have less risk of stroke or systemic embolism when taking [novel oral anticoagulants] than when taking warfarin, a finding in line with the overall effect favoring [novel oral anticoagulants] over warfarin,” the researchers wrote. “For subjects with normal renal function, the benefits of [novel oral anticoagulants] and warfarin appear to be similar.”
This activity is supported by an educational grant from Merck & Co., Inc.
This activity is supported by an educational grant from Salix, A Dvision of Valeant Pharmaceuticals North America, LLC.
New technologies advance treatment options for patients with arrhythmia disorders, HF
A look at ezetimibe and the IMPROVE-IT trial
PCSK9 inhibitors change treatment approach for dyslipidemia
This feature offers timely executive summaries of the most relevant journals in cardiology.
Snapshot summaries of recent study results in cardiology.
Your central portal for information presented at ACC 2015.
Your resource for news and videos from SCAI 2014.
This exclusive Healio resource provides you a comprehensive window into what your colleagues and key opinion leaders are saying about current and future drugs and devices and their impact on patient outcomes.
Related story »
View past polls »
Search Healio's robust listing of national and international medical meetings.
©2015 All Rights Reserved.